Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies, has granted inducement awards to five new employees under its 2024 Inducement Plan. The awards consist of 18,200 restricted stock units (RSUs) of Intellia's common stock.
The RSUs will vest in three equal installments on August 1 of 2026, 2027, and 2028, subject to continued employment. These awards were granted outside the company's stockholder-approved equity incentive plans and were approved by Intellia's compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA), un'azienda in fase clinica specializzata in terapie basate su CRISPR, ha assegnato premi di incentivo a cinque nuovi dipendenti nell'ambito del suo Piano di Incentivi 2024. I premi consistono in 18.200 unità azionarie vincolate (RSU) delle azioni ordinarie di Intellia.
Le RSU matureranno in tre tranche uguali il 1° agosto del 2026, 2027 e 2028, subordinatamente alla permanenza in azienda. Questi premi sono stati concessi al di fuori dei piani di incentivo azionario approvati dagli azionisti e sono stati autorizzati dal comitato per la remunerazione di Intellia in conformità alla Regola 5635(c)(4) del Nasdaq.
Intellia Therapeutics (NASDAQ:NTLA), una empresa en etapa clínica especializada en terapias basadas en CRISPR, ha otorgado premios de incentivo a cinco nuevos empleados bajo su Plan de Incentivos 2024. Los premios consisten en 18,200 unidades restringidas de acciones (RSU) de las acciones comunes de Intellia.
Las RSU se consolidarán en tres cuotas iguales el 1 de agosto de 2026, 2027 y 2028, sujeto a la continuidad laboral. Estos premios fueron otorgados fuera de los planes de incentivos accionarios aprobados por los accionistas y fueron aprobados por el comité de compensación de Intellia conforme a la Regla 5635(c)(4) de Nasdaq.
Intellia Therapeutics (NASDAQ:NTLA)는 CRISPR 기반 치료법을 전문으로 하는 임상 단계 유전자 편집 회사로, 2024년 유인 계획에 따라 5명의 신입 직원에게 유인 보상을 부여했습니다. 이 보상은 Intellia 보통주 18,200주의 제한 주식 단위(RSU)로 구성됩니다.
RSU는 계속 고용 조건 하에 2026년, 2027년, 2028년 8월 1일에 각각 3등분하여 권리가 확정됩니다. 이 보상은 회사 주주 승인 주식 인센티브 계획 외부에서 부여되었으며, Nasdaq 상장 규칙 5635(c)(4)에 따라 Intellia 보상 위원회의 승인을 받았습니다.
Intellia Therapeutics (NASDAQ:NTLA), une société en phase clinique spécialisée dans les thérapies basées sur CRISPR, a accordé des primes d'incitation à cinq nouveaux employés dans le cadre de son Plan d'Incitation 2024. Ces primes consistent en 18 200 unités d'actions restreintes (RSU) des actions ordinaires d'Intellia.
Les RSU seront acquises en trois versements égaux les 1er août 2026, 2027 et 2028, sous réserve de la poursuite de l'emploi. Ces primes ont été attribuées en dehors des plans d'incitation en actions approuvés par les actionnaires et ont été approuvées par le comité de rémunération d'Intellia conformément à la règle 5635(c)(4) du Nasdaq.
Intellia Therapeutics (NASDAQ:NTLA), ein klinisch tätiges Unternehmen für Geneditierung, das sich auf CRISPR-basierte Therapien spezialisiert hat, hat Anreizprämien an fünf neue Mitarbeiter im Rahmen seines Inducement-Plans 2024 vergeben. Die Prämien bestehen aus 18.200 Restricted Stock Units (RSUs) der Stammaktien von Intellia.
Die RSUs werden in drei gleichen Raten am 1. August 2026, 2027 und 2028 fällig, vorbehaltlich eines fortgesetzten Arbeitsverhältnisses. Diese Prämien wurden außerhalb der von den Aktionären genehmigten Aktienanreizpläne des Unternehmens gewährt und vom Vergütungsausschuss von Intellia gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt.
- None.
- None.
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on August 1, 2025, it awarded an inducement grant to five new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.
The inducement grant consisted of time-based restricted stock units (“RSUs”) for 18,200 shares of Intellia’s common stock, with one-third of such RSUs vesting on August 1, 2026, 2027 and 2028.
All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Brittany Chaves
Senior Manager, Investor Relations
brittany.chaves@intelliatx.com
FAQ
What type of inducement grants did Intellia Therapeutics (NTLA) announce on August 1, 2025?
How will the RSUs vest for Intellia Therapeutics' new employees?
Under which plan were Intellia Therapeutics' inducement grants awarded?
How many new employees received inducement grants from Intellia Therapeutics?
